Evoq Remedies Limited - pharma in Ahmedabad, Gujarat, India. FY 2026 financials & compliance.
CIN L46209GJ2010PLC059692 Incorporated 24 February 2010 ROC Ahmedabad HQ Ahmedabad, Gujarat, India
Under Insolvency Listed - BSE: 543500 Public Limited Company pharma
Market Cap
₹4.26 Cr
EVOQ · BSE
Share Price
₹1.79
+4.68% today
Revenue
₹25.51 Cr
FY 2025-26 · +116.9% YoY
EBITDA
−₹1.45 Cr
Margin -5.7%
Net Profit
−₹0.24 Cr
FY 2025-26 · -400.0% YoY
Authorised capital
₹42 Cr
Registered with MCA
Paid-up capital
₹24.9 Cr
Issued & subscribed
Company age
16 yrs
Est. 2010

About Evoq Remedies Limited

Data last updated:

Evoq Remedies Limited is a public limited company based in Ahmedabad, Gujarat, India. The company is currently undergoing Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency professional. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 24 February 2010.

The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L46209GJ2010PLC059692. Its GSTIN is 24AAZCS6618L1ZI (Gujarat). It is a listed company as per MCA records. Its shares are listed on BSE: 543500.

The company has an authorised share capital of ₹42 Cr and a paid-up capital of ₹24.9 Cr. It was formerly known as Evoq Remedies Private Limited and Salus Life Science and Research Private Limited. It is led by directors including Bhumishth Narendrabhai Patel (Managing Director) and Pushpa Joshi.

Its last annual general meeting (AGM) was held on 17 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Ahmedabad, Gujarat.

As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹25.51 Cr, a growth of 116.9% compared to the previous year. For the same year it recorded a net loss of ₹24 Lakh (net margin -0.9%) and EBITDA of -₹1.45 Cr (EBITDA margin -5.7%).

The company is associated with 1 brand: EVOQ Remedies. Court records list 1 case involving the company, including 1 filed by the company. The company has 51 deals on record (41 market trades, 6 secondary share transfers, 3 funding rounds), with disclosed funding of ₹60.57 Cr; the latest was in June 2026.

The last known website on record is evoqremedies.com.

Company details

CIN L46209GJ2010PLC059692
Registration Number 059692
Incorporation Date 24 February 2010
ROC Ahmedabad
Listing Status Listed - Listed on BSE (543500)
Company Status Under CIRP
Compliance Status Active Compliant

Name history

Evoq Remedies has undergone 2 name changes throughout its history. The company was previously known as Evoq Remedies Private Limited, and Salus Life Science And Research Private Limited. The current legal name is Evoq Remedies Limited.

Company NameStatus
Evoq Remedies LimitedCurrent
Evoq Remedies Private LimitedPrevious
Salus Life Science And Research Private LimitedPrevious

CIN history

Evoq Remedies has 3 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L46209GJ2010PLC059692, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L46209GJ2010PLC059692Current
U24230GJ2010PLC059692Previous
L24230GJ2010PLC059692Previous
U24230GJ2010PTC059692Previous

Contact details

Evoq Remedies Limited's registered office is in Ahmedabad, Gujarat.

  • Registered Address
    A – 1106 Empire Business Hub Near Auda Water Tank Science City Road, Sola, Ahmedabad, Gujarat, India – 380060
  • Industry
    Pharma, Drug Formulation & Development
Comprehensive company report
Evoq Remedies Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Evoq Remedies operates one associated brand: EVOQ Remedies. Each brand links to its own profile.

BrandDescriptionWebsite
CDMO focused on manufacturing pharmaceutical formulation and marketing servicesevoqremedies.com

Financials of Evoq Remedies Limited

FY 2025-26 filings available

Evoq Remedies Limited reported revenue of ₹25.51 Cr (up 116.9% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹25.51 Cr
+116.9% YoY
EBITDA
−₹1.45 Cr
+35.3% YoY
Profit After Tax
−₹0.24 Cr
-400.0% YoY
Net Worth
-
Total Assets
-
Total Debt
-

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue25.5111.764.0520.3916.7810.029.07
Revenue growth+116.9%+190.4%-80.1%+21.5%+67.5%+10.5%-
EBITDA(1.45)(2.24)(1.65)(3.73)1.450.950.00
EBITDA margin-5.7%-19.1%-40.7%-18.3%+8.6%+9.5%0.0%
Profit before tax(0.25)0.120.602.291.450.950.00
Net profit(0.24)0.080.441.621.080.710.00
Net profit margin-0.9%+0.7%+10.9%+8.0%+6.4%+7.1%0.0%
EPS (₹)(0.10)0.040.331.190.80715.450.30
Balance sheet
Total assets-44.5429.4834.3631.320.740.03
Net worth-44.5425.2424.7923.170.740.02
Total debt-0.004.249.588.160.000.01
Cash & bank-0.210.120.153.090.030.00
Net working capital-44.3129.4734.3531.320.740.03
Cash flow
Cash from operations-(14.62)5.32(4.35)(26.43)0.03(0.02)
Cash from investing-(0.26)(0.01)(0.01)0.000.000.00
Cash from financing-14.97(5.34)1.4229.490.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 22 Nov 2026
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue25.5111.764.0520.3916.7810.029.07
Revenue growth+116.9%+190.4%-80.1%+21.5%+67.5%+10.5%-
Other income1.252.412.266.020.000.000.00
Total expenses26.9614.005.7024.1215.339.079.07
Employee cost0.000.070.080.200.180.010.01
EBITDA(1.45)(2.24)(1.65)(3.73)1.450.950.00
EBITDA margin-5.7%-19.1%-40.7%-18.3%+8.6%+9.5%0.0%
Depreciation0.050.050.010.000.000.000.00
Interest0.000.000.000.000.000.000.00
Profit before tax(0.25)0.120.602.291.450.950.00
Tax(0.01)0.040.160.670.370.240.00
Net profit(0.24)0.080.441.621.080.710.00
Net profit margin-0.9%+0.7%+10.9%+8.0%+6.4%+7.1%0.0%
EPS (₹)(0.10)0.040.331.190.80715.450.30
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-24.9013.6013.6013.600.010.01
Reserves & surplus-19.6411.6411.199.570.730.01
Shareholders' funds (net worth)-44.5425.2424.7923.170.740.02
Secured loans-0.000.000.000.000.000.00
Unsecured loans-0.004.249.588.160.000.01
Total debt-0.004.249.588.160.000.01
Total liabilities-44.5429.4834.3631.320.740.03
Assets
Gross block-0.220.030.010.000.000.00
Net block-0.220.020.010.000.000.00
Capital work in progress-0.000.000.000.000.000.00
Investments-0.000.000.000.000.000.00
Inventories-2.223.132.030.780.150.06
Sundry debtors-8.621.7417.2225.406.844.72
Cash & bank balances-0.210.120.153.090.030.00
Loans & advances-38.7431.8615.494.061.030.87
Total current assets-49.7936.8534.8933.338.055.65
Total current liabilities-5.487.380.542.017.315.62
Net working capital-44.3129.4734.3531.320.740.03
Total assets-44.5429.4834.3631.320.740.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-0.120.153.090.030.000.02
Net cash from operating activities-(14.62)5.32(4.35)(26.43)0.03(0.02)
Net cash from investing activities-(0.26)(0.01)(0.01)0.000.000.00
Net cash from financing activities-14.97(5.34)1.4229.490.000.00
Net change in cash-0.09(0.03)(2.94)3.060.03(0.02)
Closing cash-0.210.120.153.090.030.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+116.9%+190.4%-80.1%+21.5%+67.5%+10.5%-
EBITDA growth+35.3%-35.8%+55.8%-357.2%+52.6%--
PBT growth--80.0%-73.8%+57.9%+52.6%+9997.0%+9997.0%
Net income growth-400.0%-81.8%-72.8%+50.0%+52.1%--
Revenue CAGR (3Y)+7.8%-11.2%-26.1%+31.0%+72.8%--
EBITDA CAGR (3Y)-27.0%---+425.4%--
Profitability & leverage
Net income margin-0.9%+0.7%+10.9%+8.0%+6.4%+7.1%0.0%
Return on capital employed-+0.4%+1.9%+7.0%+9.1%+249.4%0.0%
Return on net worth-+0.3%+1.8%+6.8%+9.1%+189.5%0.0%
Debt / equity-0.060.280.370.340.010.25
Long-term debt / equity-0.000.000.000.000.010.25
Interest cover0.000.000.000.000.000.00-
Efficiency & per share
Fixed asset turnover-94.08202.504,078.000.000.000.00
Inventory turnover-4.401.5714.5136.0995.43201.56
Debtors turnover-2.270.430.961.041.733.05
EPS (₹)(0.10)0.040.331.190.80715.450.30
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.0017.8918.5618.2217.03743.0222.60

To see the full year-wise statements and ratios of Evoq Remedies Limited, buy the company report.

Board of directors of Evoq Remedies Limited

Evoq Remedies has 4 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.

Directors (as last reported)
NameDesignationAppointment DateTenureStatus
Bhumishth Narendrabhai PatelManaging Director01 Aug 20242 Years 3 MonthsAs last reported
Pushpa JoshiDirector31 Mar 20251 Years 7 MonthsAs last reported
Harsh Mahendrakumar KothariDirector06 Sep 20242 Years 2 MonthsAs last reported
Narendrakumar Gangaramdas PatelDirector11 Sep 20233 Years 2 MonthsAs last reported

Deals & funding

Evoq Remedies Limited has 51 deals on record (41 market trades, 6 secondary share transfers, 3 funding rounds), with disclosed funding of ₹60.57 Cr; the latest was in June 2026.

Total deals
51
Market trades
41
Secondary share transfers
6
Funding rounds
3
IPO
1
Disclosed funding
₹60.57 Cr

Deals on record (5 of 51)

WhenDealAmountParties
Jun 2025Market trade₹6.1 LakhBuyer: Yashiv Holdings Private Limited
Seller: an individual
May 2025Market trade₹6.1 LakhSeller: Multiplier Share and Stock Advisors Private Limited
Feb 2025Market trade₹21.1 LakhSeller: Mansi Share and Stock Broking Private Limited , an individual
Feb 2025Market trade₹1.33 CrBuyer: Mansi Share and Stock Broking Private Limited , 2 individuals
Seller: 2 individuals
Feb 2025Market trade₹62 LakhBuyer: Setu Securities Private Limited , Priyasha Meven Finance Limited , an individual
Seller: Setu Securities Private Limited , Multiplier Share and Stock Advisors Private Limited , Priyasha Meven Finance Limited , an individual

To see the full deal history of Evoq Remedies Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Evoq Remedies Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

Evoq Remedies has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
24AAZCS6618L1ZIGujaratActive27 Nov 2018

To see the full GST registrations and return filing status of Evoq Remedies Limited, buy the company report.

Recent activity

Evoq Remedies Limited has 14 board changes on record since 2023: 4 appointments and 10 cessations. The latest: Pushpa Joshi ceased to be Additional Director on 02 Jun 2025.

Filing
Evoq Remedies Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
AGM
Evoq Remedies Limited last Annual general meeting of members was held on 17 Sep 2025 as per latest MCA records.
Ceased
Pushpa Joshi ceased to be Additional Director.
Ceased
Aesha Harsh Shah ceased to be Additional Director.
Appointed
Pushpa Joshi was appointed as Director.
Ceased
Pranav Manoj Vajani ceased to be Director.
Ceased
Harsh Kothari ceased to be Additional Director.
Ceased
Digesh Mansukhlal Deshaval ceased to be Director.
Appointed
Harsh Mahendrakumar Kothari was appointed as Director.
Appointed
Bhumishth Narendrabhai Patel was appointed as Managing Director.
Ceased
Narendrakumar Gangaramdas Patel ceased to be Additional Director.
Ceased
Dahyabhai Mafatlal Patel ceased to be Managing Director.

5 earlier events are in the company report.

Frequently asked questions

Evoq Remedies is undergoing "Corporate Insolvency Resolution Process" (CIRP) under the Insolvency and Bankruptcy Code, 2016. Management control has been transferred to an insolvency resolution professional. The company may not be able to independently enter into new commitments during this period. This is a high-risk status - verify the resolution status before any engagement.

Evoq Remedies is a company under insolvency, formerly operating as a public limited company based in Ahmedabad, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 24 February 2010 and is registered under CIN L46209GJ2010PLC059692. Listed on BSE: 543500. Caution is advised - the company may not have the legal capacity to fulfil new agreements.

Evoq Remedies reported revenue of ₹25.51 Cr for FY 2025-26 (up 116.9% YoY) based on standalone financials.

Evoq Remedies has 4 current directors:

The latest financial statements of Evoq Remedies on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 17 September 2025. Year-wise statements from 2015 are in the company report.

The CIN (Corporate Identification Number) of Evoq Remedies is L46209GJ2010PLC059692. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Evoq Remedies is a listed company as per MCA records. Its shares are listed on BSE (code: 543500).

Evoq Remedies has 1 court case on record: 1 filed by the company.

Evoq Remedies was incorporated on 24 February 2010. It is registered with the Registrar of Companies, Ahmedabad.

Evoq Remedies has 51 deals on record (41 market trades, 6 secondary share transfers, 3 funding rounds), with disclosed funding of ₹60.57 Cr; the latest was in June 2026.